Open Access Article
Article

Management of Side Effects of Novel Therapies for Multiple Myeloma: Consensus Statements Developed by the International Myeloma Foundation's Nurse Leadership Board

Page A. Bertolotti

Elizabeth Bilotti

Kathleen Colson

Kathleen Curran

Deborah Doss

Beth Faiman

Maria Gavino

Bonnie S. Jenkins

Kathryn E. Lilleby

Ginger Love

Patricia Mangan

Emily J. McCullagh

Teresa Miceli

Kena C. Miller

Kathryn Rogers

Sandra Rome

Stacey Sandifer

Lisa C. Smith

Joseph D. Tariman

Jeanne Westphal

adverse event management, thalidomide
CJON 2008, 12(3), 9-12. DOI: 10.1188/08.CJON.S1.9-12

Nurses play an essential role in managing the care of patients with multiple myeloma, who require education and support to receive and adhere to optimal therapy. The International Myeloma Foundation created a Nurse Leadership Board comprised of oncology nurses from leading cancer centers and community practices. An assessment survey identified the need for specific recommendations for managing key side effects of novel antimyeloma agents. Myelosuppression, thromboembolic events, peripheral neuropathy, steroid toxicities, and gastrointestinal side effects were selected for the first consensus statements. The board developed recommendations for healthcare providers in any medical setting, including grading of side-effect toxicity and strategies for managing the side effects in general, with specific recommendations pertaining to the novel agents.

Jump to a section

    References

    American Cancer Society. (2008). Cancer facts and figures 2008. Atlanta, GA: Author.
    Bertolotti, P., Bilotti, E., Colson, K., Curran, K., Doss, D., Faiman, B., et al. (2007). Nursing guidelines for enhanced patient care [Abstract]. Haematologica, 92(Suppl. 2), 211.
    Celgene Corporation. (2007a). Revlimid® (lenalidomide) [Package insert]. Summit, NJ: Author.
    Celgene Corporation. (2007b). Thalomid® (thalidomide) [Package insert]. Summit, NJ: Author.
    Faiman, B., Bilotti, E., Mangan, P. A., Rogers, K., & the IMF Nurse Leadership Board. (2008). Steroid-associated side effects in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board. Clinical Journal of Oncology Nursing, 12(3, Suppl.), 53-62.
    Ghobrial, J., Ghobrial, I. M., Mitsiades, C., Leleu, X., Hatjiharissi, E., Moreau, A. S., et al. (2007). Novel therapeutic avenues in myeloma: Changing the treatment paradigm. Oncology, 21(7), 785-792.
    Kyle, R., & Rajkumar V. (2004). Multiple myeloma. New England Journal of Medicine, 351(18), 1860-1873.
    Manochakian, R., Miller, K., & Chanan-Khan, A. A. (2007). Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. Oncologist, 12(8), 978-990.
    Miceli, T., Colson, K., Gavino, M., Lilleby, K., & the IMF Nurse Leadership Board. (2008). Myelosuppression associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board. Clinical Journal of Oncology Nursing, 12(3, Suppl.), 13-19.
    Millennium Pharmaceuticals, Inc. (2007). Velcade® (bortezomib) [Package insert]. Cambridge, MA: Author.
    National Cancer Institute. (2006). Common Terminology Criteria for Adverse Events (CTCAE), v3.0. Retrieved September 17, 2007, from http://ctep.cancer.gov/forms/CTCAEv3.pdf
    National Comprehensive Cancer Network. (2008). NCCN Clinical Practice Guidelines in Oncology™: Multiple myeloma [v.1.2008]. Retrieved December 31, 2007, from http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf
    Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., et al. (2005). Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 106(13), 4050-4053.
    Richardson, P., & Anderson, K. (2006). Thalidomide and dexamethasone: A new standard of care for initial therapy in multiple myeloma. Journal of Clinical Oncology, 24(3), 334-336.
    Richardson, P. G., Hideshima, T., Mitsiades, C., & Anderson, K. C. (2007). The emerging role of novel therapies for the treatment of relapsed myeloma. Journal of the National Comprehensive Cancer Network, 5(2), 149-162.
    Rome, S., Doss, D., Miller, K. C., Westphal, J., & the IMF Nurse Leadership Board. (2008). Thromboembolic events associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board. Clinical Journal of Oncology Nursing, 12(3, Suppl.), 21-27.
    Smith, L. C., Bertolotti, P., Curran, K., Jenkins, B., & the IMF Nurse Leadership Board. (2008). Gastrointestinal intestinal side effects associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board. Clinical Journal of Oncology Nursing, 1212(3, Suppl.), 37-51.
    Tariman, J. D. (2003). Understanding novel therapeutic agents for multiple myeloma. Clinical Journal of Oncology Nursing, 7(5), 521-528.
    Tariman, J. D., Love, G., McCullagh, E., Sandifer, S., & the IMF Nurse Leadership Board. (2008). Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board. Clinical Journal of Oncology Nursing, 12(3, Suppl.), 29-35.